Advances in Systemic Therapy of Differentiated Thyroid Cancer in Second Line and Beyond

Lori Wirth, MD, provides an overview of differentiated thyroid cancer including patient presentation and disease course.

Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.

Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.

Lori Wirth, MD, discusses the unmet needs and ongoing trials in development for patients with RR-DTC.

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.

Lori Wirth, MD, provides an overview of differentiated thyroid cancer including treatment options that are currently available, as well as sharing insights on emerging therapies.